A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life

详细信息    查看全文

• 作者：Akira Mizuki ; MD¹ ; ^{amizuki@highway.ne.jp} ; Masayuki Tatemichi ; MD ; PhD² ; Terue Sakakibara ; MD³ ; Yukihiko Miura ; MD⁴ ; Shigeyuki Zeki ; MD⁵ ; Mitsuru Ohata ; MD⁶ ; Kenji Matsuo ; MD⁷ ; Fumio Kawamura ; MD⁸ ; Hiroshi Nagata ; MD²
• 关键词：proton-pump inhibitor ; quality of life ; refractory gastroesophageal reflux disease ; sleep disturbances
• 刊名：Current Therapeutic Research
• 出版年：2016
• 出版时间：2016
• 年：2016
• 卷：79
• 期：Complete
• 页码：1-7
• 全文大小：347 K
• 卷排序：79

文摘

This multicenter prospective randomized comparative study compares the efficacy on symptoms, QOL and sleep disturbance between two ways of double dose PPI; once-daily 20mg RPZ or twice-daily 10mg RPZ. The patients with PPI refractory GERD were suffered from severe acid reflux symptoms, sleep disturbance and general distress. For these reasons, to establish the treatments to refractory GERD was important to improve their QOL. In patients with refractory GERD, there was no significant difference in GOS, PSQI, or recurrence rate between the groups.